<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Malignant (necrotizing) external otitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Malignant (necrotizing) external otitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Malignant (necrotizing) external otitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Rubin Grandis, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malignant (necrotizing) external otitis (also termed malignant otitis externa) is an invasive infection of the external auditory canal and skull base, which typically occurs in older adult patients with diabetes mellitus. Increasing reports of malignant external otitis in patients infected with the human immunodeficiency virus (HIV) implicate a compromised immune system as a predisposing factor in this disease.</p><p><em>Pseudomonas aeruginosa</em> is nearly always the responsible organism. The widespread use of oral and topical fluoroquinolones for the treatment of otitis may make the isolation of <em>P. aeruginosa</em> more difficult and has contributed to the emergence of <em>P. aeruginosa</em> resistant to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> [<a href="#rid1">1,2</a>].</p><p>The epidemiology, pathogenesis, clinical features, and management of malignant external otitis will be reviewed here. The spectrum of ear and eye infections due to <em>P. aeruginosa</em> and other clinical syndromes caused by this pathogen are discussed separately. (See  <a class="medical medical_review" href="/d/html/3148.html" rel="external">"Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system", section on 'Ear infections'</a> and  <a class="medical medical_review" href="/d/html/3148.html" rel="external">"Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system", section on 'Eye infections'</a> and  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a> and  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p>An overview of external otitis is also presented separately. (See  <a class="medical medical_review" href="/d/html/6866.html" rel="external">"External otitis: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Older adults diabetic patients are overwhelmingly the population at risk for malignant external otitis. More than 90 percent of adults with this disease were found to have some form of glucose intolerance in one review [<a href="#rid1">1</a>]. A number of hypotheses have been advanced to explain this predisposition in diabetics including:</p><p class="bulletIndent1"><span class="glyph">●</span>Microangiopathy in the ear canal, which might also occur more commonly in older adult individuals [<a href="#rid3">3,4</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased pH in diabetic cerumen [<a href="#rid5">5,6</a>]</p><p></p><p>However, susceptibility to malignant external otitis has not been correlated with the level of glucose intolerance [<a href="#rid3">3</a>].</p><p>By contrast, malignant external otitis is a rare disease in children with fewer than 20 cases reported in the literature. Affected children are more likely to be immunocompromised (eg, malignancy or malnutrition). Children tend to develop fever and leukocytosis in association with this infection and are more likely than adults to have a concomitant <em>P. aeruginosa</em> bacteremia [<a href="#rid3">3</a>].</p><p>There are several reports of malignant external otitis in patients infected with HIV [<a href="#rid7">7-14</a>]. In seven such cases, none of the patients were diabetic and were adults younger than classic patients with this infection. </p><p>Recent ear surgery and hearing aid irritation may be risk factors for malignant otitis externa [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>Malignant external otitis is caused by <em>P. aeruginosa</em> in more than 95 percent of cases. When more than one organism is recovered, isolates accompanying <em>P. aeruginosa</em> tend to be normal skin flora. Occasional reports of cases caused by other organisms have included <em>Aspergillus</em> species [<a href="#rid14">14,16-21</a>], <em>Staphylococcus aureus</em> [<a href="#rid22">22</a>], <em>Proteus mirabilis</em> [<a href="#rid23">23</a>], <em>Klebsiella oxytoca</em> [<a href="#rid24">24</a>], <em>Burkholderia cepacia</em> [<a href="#rid25">25</a>], and <em>Candida parapsilosis</em> [<a href="#rid26">26</a>]. Infection with these other organisms characteristically occurs in immunocompromised hosts, such as those with acquired immunodeficiency syndrome (AIDS) or cancer. Among seven cases reported in HIV-infected patients, for example, <em>Aspergillus fumigatus</em> was isolated in three. While most cases of fungal malignant external otitis are due to <em>Aspergillus</em>, other fungi have also been reported, including <em>Scedosporium apiospermum</em>, <em>Pseudallescheria boydii</em>, <em>Candida ciferrii</em>, <em>Candida orthopsilosis </em>[<a href="#rid27">27</a>]<em>,</em> and <em>Malassezia sympodialis</em> [<a href="#rid28">28,29</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is a ubiquitous gram-negative bacterium that is capable of growing in distilled water [<a href="#rid30">30,31</a>]. Since it is not a normal component of ear canal flora even in diabetic patients, its recovery indicates the presence of a pathogen [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p>Contamination of water with <em>Pseudomonas</em> has been directly linked to simple external otitis [<a href="#rid32">32,35</a>]. We previously reported a case-control study designed to test the hypothesis that aural water exposure contributed to the development of malignant external otitis. In this study, patients with the disease had a statistically more frequent antecedent history of ear irrigation (generally for the purposes of removing cerumen) compared with matched controls [<a href="#rid36">36</a>]. Many reports have subsequently confirmed this association between aural water exposure and malignant external otitis [<a href="#rid4">4,37-41</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with malignant external otitis classically present with exquisite otalgia and otorrhea, which are not responsive to topical measures used to treat simple external otitis. The pain is generally more severe than that found in simple external otitis, although the two may be difficult to distinguish in their early stages. The pain in malignant external otitis tends to be nocturnal and extend into the temporomandibular joint, resulting in pain with chewing.</p><p>On physical examination, granulation tissue is frequently visible in the inferior portion of the external auditory canal at the bone-cartilage junction (at the site of Santorini's fissures). However, this finding may be absent in atypical patients (eg, immunocompromised individuals and children).</p><p>As the infection advances, osteomyelitis of the base of the skull and temporomandibular joint osteomyelitis can develop [<a href="#rid3">3,6,42,43</a>]. Progression of the osteomyelitis can be associated with cranial nerve palsies. In one series of 23 adult diabetic patients with malignant external otitis, 10 patients had cranial nerve involvement, six had only facial nerve involvement, and four had a combination of nerves involved (VI, VII, IX, X, XI, XII) [<a href="#rid44">44</a>]. Children with malignant external otitis have a higher incidence of facial palsy due to their relatively undeveloped mastoid process and the more medial location of the fissures of Santorini, which places the facial nerve in closer proximity to the ear canal [<a href="#rid45">45</a>]. The glossopharyngeal, vagal, and spinal accessory nerves can be afflicted at the jugular foramen, and the hypoglossal nerve can be affected as it exits the hypoglossal canal. The trigeminal and abducens nerves are rarely affected at the petrous apex, and there is a single report of optic nerve involvement in a patient with malignant external otitis [<a href="#rid46">46</a>]. The olfactory, oculomotor, and trochlear nerves appear to be unaffected by this disease.</p><p>Other central nervous system complications are rare but can be fatal when they occur. These include meningitis, brain abscess, dural sinus thrombosis, or pseudoaneurysm of the intrapetrous internal carotid artery [<a href="#rid38">38,47</a>]. (See  <a class="medical medical_review" href="/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a> and  <a class="medical medical_review" href="/d/html/3410.html" rel="external">"Septic dural sinus thrombosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis is often overlooked, leading to delay in effective therapy [<a href="#rid3">3,15</a>]. In the absence of a single pathognomonic criterion, the diagnosis of malignant external otitis is based upon a constellation of clinical, laboratory, and radiographic findings. A retrospective review of 73 cases at a tertiary care center suggested that patients who present with most of the classic clinical and radiographic criteria and/or who fail to respond to the initial course of intensive therapy have worse outcomes [<a href="#rid48">48</a>]. Individuals noted to have "severe" disease at presentation as manifest by cranial nerve palsy, positive fungal culture, relapse, and invasion on imaging have a worse treatment outcome [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H7"><span class="h2">General laboratory findings</span><span class="headingEndMark"> — </span>Laboratory parameters are generally normal in malignant external otitis, with the exception of an elevated erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP). Although nonspecific, a strikingly elevated ESR or CRP is the most characteristic laboratory abnormality and is a useful way of monitoring disease activity [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4079083170"><span class="h2">Microbiology studies</span><span class="headingEndMark"> — </span>Cultures of ear canal drainage, or granulations, should be performed and sent for Gram stain and culture for bacteria. Stains (eg, calcofluor) and cultures for fungi should also be sent. </p><p>Although bacteremia is rare in necrotizing otitis externa in adults, it is reasonable to send blood cultures prior to starting antibiotics. Immunocompromised patients and children in particular may be bacteremic without overt signs of toxicity. </p><p class="headingAnchor" id="H8"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>The utility of nuclear imaging studies is controversial, whereas anatomic localizing procedures such as computed tomography (CT) and magnetic resonance imaging (MRI) can be useful for both diagnosis and follow-up.</p><p class="headingAnchor" id="H11"><span class="h3">Computed tomography and magnetic resonance imaging</span><span class="headingEndMark"> — </span>Anatomic imaging modalities allow for both anatomic localization of disease as well as the assessment of disease resolution. CT scanning is ideal for the assessment of bone erosion. In a prospective study, we determined that the presence of bone erosion and/or soft tissue abnormalities in the subtemporal region was helpful in making the diagnosis of malignant external otitis [<a href="#rid50">50</a>]. Although bone did not remineralize, resolution of the soft tissue component did correlate with disease activity. While some studies indicate that CT findings predict clinical outcome [<a href="#rid51">51</a>], others have reported that the CT findings do not correlate with the clinical course [<a href="#rid52">52</a>]. Analysis of CT and MRI in 18 patients with malignant external otitis confirmed that these radiographic modalities provide complementary information [<a href="#rid53">53</a>].</p><p>To compare CT with MRI, we performed a long-term prospective study in seven patients with malignant external otitis [<a href="#rid54">54</a>]. MRI was slightly better at demonstrating medial skull base disease due to its ability to delineate changes in the fat content of the marrow. Better results with MRI have also been noted by others [<a href="#rid55">55</a>]. Anterior extension into the retrocondylar fat on MRI may indicate the earliest change in malignant external otitis, with extension in more than one direction (eg, anterior, medial, midline, intracranial, extracranial) being associated with worse prognosis [<a href="#rid56">56</a>]. Since bone erosion distinguishes malignant external otitis from external otitis, CT is the better test for initial diagnosis of bone erosion, although this may be absent in very early presentations of malignant external otitis. MRI is better for establishing extent of disease and monitoring response to therapy. MRI may also identify very early cases prior to appearance of bony erosion on CT. MRI can also be used to distinguish skull base osteomyelitis secondary to malignant external otitis from nasopharyngeal carcinoma [<a href="#rid57">57</a>]. One group has proposed a radiologic stratification for malignant external otitis ranging from phase I (inflammation limited to the external auditory canal without bony erosion) to phase V (inflammation extending to the contralateral ear/skull base) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H4079083289"><span class="h3">Gallium scan</span><span class="headingEndMark"> — </span>Gallium citrate (Ga-67) scanning appears to be more specific than bone scanning since the radioisotope is incorporated into granulocytes and bacteria. Although several studies have reported that gallium scanning can be used to follow disease activity, others have noted that normal scans can be found in patients with recurrent disease [<a href="#rid59">59-65</a>]. The combination of Ga-67 with single photon emission computerized tomography (SPECT) scanning may be useful in the diagnosis and follow-up examination [<a href="#rid15">15,63-65</a>]. However, it has not been compared with CT plus MRI. (See <a class="local">'Computed tomography and magnetic resonance imaging'</a> above.)</p><p class="headingAnchor" id="H4079083582"><span class="h3">Bone scan</span><span class="headingEndMark"> — </span>Bone scanning with technetium (Tc 99m), where the radionuclide tracer accumulates at sites of osteoblastic activity, is very sensitive in making the diagnosis. However, it is not a specific study since there are reports of positive bone scans in simple external otitis [<a href="#rid66">66</a>], and bone scans are not suitable for following response to treatment since they do not normalize. Quantitative bone scanning may be able to distinguish simple from malignant external otitis and demonstrate disease resolution [<a href="#rid67">67,68</a>]. Use of the mouse monoclonal antibody linked to technetium (Tc 99m sulesomab), which is approved for osteomyelitis imaging, was reported in two cases of malignant external otitis where imaging results appeared to accurately reflect disease activity and response to treatment [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Squamous cell carcinoma of the temporal bone can also present as a painful draining ear canal. Since radiographic studies cannot differentiate tumor from necrotizing infection, biopsy is the only definitive method to distinguish between these two entities. A positive culture for <em>P. aeruginosa</em> and elevation of the ESR and/or CRP are more commonly associated with infection. There are only two reports of simultaneous presentation of temporal bone cancer and malignant external otitis [<a href="#rid70">70,71</a>].</p><p>The other mimic of malignant external otitis caused by <em>P. aeruginosa</em> is malignant external otitis caused by <em>Aspergillus</em> spp or, very rarely, other pathogens. Since malignant external otitis caused by <em>P. aeruginosa</em> is far more common than either carcinoma of the temporal bone or malignant external otitis caused by <em>Aspergillus</em> spp, we generally reserve biopsy for patients who have not responded to therapy for <em>P. aeruginosa</em> infection.</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H4119386627"><span class="h2">Systemic antimicrobial therapy</span><span class="headingEndMark"> — </span>Antipseudomonal antimicrobials are the mainstay of therapy for malignant external otitis. The optimal approach to initial empiric regimen selection is uncertain. Our approach to treatment depends on the severity of disease. The local rate of fluoroquinolone resistance in <em>Pseudomonas</em> may also be a consideration. </p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompetent patients with uncomplicated malignant otitis externa, we suggest <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> monotherapy. </p><p></p><p class="bulletIndent1">We usually initiate treatment with intravenous (IV) <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (in adults: 400 mg IV every eight hours; in children: 20 to 30 mg/kg per day IV divided every 12 hours, max 800 mg/day) until we observe a subjective clinical response and/or a decrease in erythrocyte sedimentation rate or C-reactive protein. At that point, the patient can be transitioned to oral ciprofloxacin (in adults: 750 mg orally every 12 hours; in children: 20 to 30 mg/kg per day orally divided every 12 hours, max 1500 mg/day). Patients taking ciprofloxacin along with medications that may interfere with absorption (eg, iron or calcium supplements) should space these appropriately to prevent interference with absorption. <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> is also likely to be effective since it has activity again<em>st P. aeruginosa</em>, but clinical experience with levofloxacin has not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with advanced malignant otitis externa (eg, significant bony erosion, multiple cranial neuropathies) or immunocompromising conditions or when the local rate of fluoroquinolone resistance in <em>Pseudomonas</em> is very high, we suggest initial combination therapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> plus an antipseudomonal beta-lactam (see below for dosing). Once there has been clinical improvement, patients can be switched to ciprofloxacin alone.</p><p></p><p class="bulletIndent1">The objective of combination therapy is to increase the likelihood of using an active agent in a patient for whom ineffective antibiotic therapy could lead to progressive disease with high morbidity. However, no studies have compared initial empiric combination therapy versus monotherapy with <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> in severe cases of malignant otitis externa. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p></p><p>With the introduction and widespread use of both oral and topical fluoroquinolones, less severe clinical presentations of malignant external otitis and the emergence of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> resistance have been increasing [<a href="#rid1">1,72-74</a>]. Patients who have failed to improve on a fluoroquinolone (eg, persistent symptoms or persistently elevated inflammatory markers) warrant biopsy for culture and susceptibility testing.</p><p>If cultures yield fluoroquinolone-resistant <em>P. aeruginosa</em>, they should be treated with an antipseudomonal antibiotic. If <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> is available, we prefer it to <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, but piperacillin-tazobactam or an antipseudomonal cephalosporin may be used if piperacillin is not available (it is not available in the United States). We do not recommend combination therapy with an aminoglycoside since ototoxicity with vestibular disturbances has occurred despite assiduous monitoring of aminoglycoside serum concentrations.</p><p>The dosing of antipseudomonal beta-lactams is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">Piperacillin</a> – In adults: 3 g IV every four hours or 4 g IV every six hours; in children: 50 to 75 mg/kg IV every four to six hours (not to exceed 4 g per dose or 24 g per day). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">Piperacillin-tazobactam</a> – In adults, 4.5 g IV every six hours; in children ≤40 kg, 300 mg/kg of the <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> component per day IV divided every eight hours (not to exceed 16 g per day of the piperacillin component); in children &gt;40 kg, 3 g every six hours or 4 g every six to eight hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a> – In adults: 2 g IV every eight hours; in children: 100 to 150 mg/kg per day IV divided every eight hours (not to exceed 6 g per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> – In adults: 2 g IV every 12 hours is the standard dose (some clinicians use 2 g IV every eight hours initially for severe <em>P. aeruginosa</em> infections); in children: 50 mg/kg IV every eight hours (not to exceed 2 g per dose). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a> – In adults: 2 g IV every eight hours; in children: 60 mg/kg per day IV divided every eight hours (not to exceed 3 g per day). If intracranial extension is a concern, 120 mg/kg per day IV divided every eight hours (not to exceed 6 g per day) should be employed.</p><p></p><p>Whether a fluoroquinolone or antipseudomonal beta-lactam is used, prolonged treatment of malignant otitis externa for six to eight weeks is generally recommended, as indicated for osteomyelitis. </p><p>If <em>Aspergillus</em> species are the causative organisms, prolonged treatment (&gt;12 weeks) with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> may be the therapy of choice [<a href="#rid75">75,76</a>]. Alternative therapy is with <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a>, which decreases the nephrotoxicity of <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>. Voriconazole was superior to amphotericin in a randomized controlled trial of patients with other types of invasive <em>Aspergillus</em> infections (primarily pulmonary) [<a href="#rid77">77</a>]. <a class="drug drug_general" data-topicid="100324" href="/d/drug information/100324.html" rel="external">Isavuconazole</a>, a new triazole shown to be noninferior to voriconazole in treating invasive <em>Aspergillus</em> infections [<a href="#rid78">78</a>], may be another option for treating <em>Aspergillus</em> malignant otitis externa, but no such cases have been described. Success has also been reported with a short course of amphotericin B and long-term oral <a class="drug drug_general" data-topicid="8586" href="/d/drug information/8586.html" rel="external">itraconazole</a> in a single case report [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a> and  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p>Most of the supportive evidence for antipseudomonal antibiotics for the treatment of malignant external otitis is observational. Cases are rare, and thus randomized controlled comparisons of therapy are not feasible. Prior to the development of systemic agents, recurrences of malignant external otitis were frequent, and mortality was approximately 50 percent [<a href="#rid4">4</a>]. The introduction of parenteral semisynthetic penicillins reduced the mortality to 20 percent [<a href="#rid80">80</a>], and a further reduction in mortality to 5 to 10 percent has occurred since the introduction of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> and antipseudomonal cephalosporins, such as <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> and <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>. Studies from 1988 to 1991 showed that prolonged therapy with ciprofloxacin alone was effective in treating most cases of malignant otitis externa [<a href="#rid81">81-87</a>], although, as above, resistance to fluoroquinolones has been increasing. </p><p>There have been reports of tendon inflammation and/or rupture with fluoroquinolones in all age groups; risk may be increased with concurrent glucocorticoids, in solid organ transplant recipients, and in patients &gt;60 years of age. In some studies in children, an increased incidence of reversible adverse events involving joints or surrounding tissues has been observed, but no compelling published evidence supports the occurrence of sustained injury to developing bones or joints in children treated with available fluoroquinolones [<a href="#rid88">88-92</a>]. The risks and benefits should be considered if a fluoroquinolone is prescribed in a child younger than 18 years of age. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Tendinopathy'</a>.) </p><p>Furthermore, fluoroquinolones have been associated with numerous other adverse effects, including hypoglycemia, central nervous system dysfunction, neuropathy, and aortic aneurysm and dissection. Fluoroquinolones may also predispose to arrhythmias due to QTc prolongation, and a baseline electrocardiogram (EKG) before and after initiating fluoroquinolones is appropriate. The US Food and Drug Administration (FDA) has issued several black box warnings and special alerts about fluoroquinolones. Specific risk factors for developing these side effects have not been identified in many cases (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H93060194"><span class="h2">Interventions with limited role</span><span class="headingEndMark"> — </span>There is no role for topical antibiotics in malignant external otitis therapy. Instillation of antipseudomonal topical agents may only increase the difficulty in isolating the organism from the ear canal. Surgical excision also plays no role in the current treatment of this disease, although this modality was used prior to the availability of systemic antipseudomonal antibiotics. Debridement and/or biopsy to rule out cancer are the only indicated surgical procedures.</p><p>Hyperbaric oxygen has been used on occasion with mixed results and may be considered as an adjuvant treatment for refractory cases [<a href="#rid42">42,93-96</a>]. However, a Cochrane review found no randomized controlled trials comparing hyperbaric oxygen therapy to treatment with antibiotics and/or surgery and concluded that there was no clear evidence to demonstrate the efficacy of hyperbaric oxygen treatment [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H4167644665"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109085.html" rel="external">"Society guideline links: Acute otitis media, otitis media with effusion, and external otitis"</a>.)</p><p class="headingAnchor" id="H24759399"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15736.html" rel="external">"Patient education: Outer ear infection (The Basics)"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3998.html" rel="external">"Patient education: External otitis (including swimmer's ear) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5155068"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> − Malignant (necrotizing) external otitis (also termed malignant otitis externa) is an invasive infection of the external auditory canal and skull base, which typically occurs in older adult patients with diabetes mellitus. (See <a class="local">'Introduction'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> − Malignant external otitis is caused by <em>Pseudomonas aeruginosa</em> in more than 95 percent of cases. Since <em>P. aeruginosa</em> is not a normal component of ear canal flora even in diabetic patients, its recovery indicates the presence of a pathogen. Occasional reports of cases caused by other organisms have included <em>Aspergillus</em> species, <em>Staphylococcus aureus</em>, <em>Proteus mirabilis</em>, <em>Klebsiella oxytoca</em>, <em>Burkholderia cepacia</em>, and <em>Candida parapsilosis</em>. Infection with these other organisms characteristically occurs in immunocompromised hosts, such as those with AIDS or cancer. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> − Patients with malignant external otitis classically present with exquisite otalgia and otorrhea, which are not responsive to topical measures used to treat simple external otitis. The pain is generally more severe than that found in simple external otitis, although the two may be difficult to distinguish in their early stages. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> − As the infection advances, osteomyelitis of the base of the skull and temporomandibular joint osteomyelitis can develop. Progression of the osteomyelitis can be associated with cranial nerve palsies. Other central nervous system complications are rare but can be fatal when they occur. These include meningitis, brain abscess, and dural sinus thrombosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> − The diagnosis of malignant external otitis is based upon a constellation of clinical, laboratory, and radiographic findings. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging −</strong> Anatomic localizing procedures, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans, can be useful for both diagnosis and follow-up. CT is the better test for identifying bony erosion, while MRI is better for establishing extent of disease and monitoring response to therapy. MRI may also identify very early cases prior to appearance of bony erosion on CT. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong> − For empiric therapy of immunocompetent patients with uncomplicated malignant external otitis, we suggest <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Initial combination therapy with ciprofloxacin plus an antipseudomonal beta-lactam is appropriate for patients with advanced infection or severe immunocompromising conditions; they can be transitioned to ciprofloxacin following clinical improvement. (See <a class="local">'Systemic antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> − The duration of antibiotic treatment is generally six to eight weeks, as indicated for osteomyelitis. Patients with treatment failure should undergo biopsy for culture and susceptibility testing. (See <a class="local">'Systemic antimicrobial therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H1575708757"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Victor L Yu, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rubin Grandis J, Branstetter BF 4th, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 2004; 4:34.</a></li><li><a class="nounderline abstract_t">Bernstein JM, Holland NJ, Porter GC, Maw AR. Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. J Laryngol Otol 2007; 121:118.</a></li><li><a class="nounderline abstract_t">Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 1988; 85:391.</a></li><li><a class="nounderline abstract_t">Chandler JR. Malignant external otitis. Laryngoscope 1968; 78:1257.</a></li><li><a class="nounderline abstract_t">Barrow HN, Levenson MJ. Necrotizing 'malignant' external otitis caused by Staphylococcus epidermidis. Arch Otolaryngol Head Neck Surg 1992; 118:94.</a></li><li><a class="nounderline abstract_t">Farr RC, Gardner G, Acker JD, et al. Blastomycotic cranial osteomyelitis. Am J Otol 1992; 13:582.</a></li><li><a class="nounderline abstract_t">Scott CF Jr, Tsurufuji M, Lu CY, et al. Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. J Immunol 1984; 132:633.</a></li><li><a class="nounderline abstract_t">Reiss P, Hadderingh R, Schot LJ, Danner SA. Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS. AIDS 1991; 5:605.</a></li><li><a class="nounderline abstract_t">Rivas Lacarte MP, Pumarola Segura F. [Malignant otitis externa and HIV antibodies. A case report]. An Otorrinolaringol Ibero Am 1990; 17:505.</a></li><li><a class="nounderline abstract_t">McElroy EA Jr, Marks GL. Fatal necrotizing otitis externa in a patient with AIDS. Rev Infect Dis 1991; 13:1246.</a></li><li><a class="nounderline abstract_t">Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection. Clin Infect Dis 1992; 14:403.</a></li><li><a class="nounderline abstract_t">Weinroth SE, Schessel D, Tuazon CU. Malignant otitis externa in AIDS patients: case report and review of the literature. Ear Nose Throat J 1994; 73:772.</a></li><li><a class="nounderline abstract_t">Ress BD, Luntz M, Telischi FF, et al. Necrotizing external otitis in patients with AIDS. Laryngoscope 1997; 107:456.</a></li><li><a class="nounderline abstract_t">Muñoz A, Martínez-Chamorro E. Necrotizing external otitis caused by Aspergillus fumigatus: computed tomography and high resolution magnetic resonance imaging in an AIDS patient. J Laryngol Otol 1998; 112:98.</a></li><li><a class="nounderline abstract_t">Jacobsen LM, Antonelli PJ. Errors in the diagnosis and management of necrotizing otitis externa. Otolaryngol Head Neck Surg 2010; 143:506.</a></li><li><a class="nounderline abstract_t">Cunningham M, Yu VL, Turner J, Curtin H. Necrotizing otitis externa due to Aspergillus in an immunocompetent patient. Arch Otolaryngol Head Neck Surg 1988; 114:554.</a></li><li><a class="nounderline abstract_t">Petrak RM, Pottage JC, Levin S. Invasive external otitis caused by Aspergillus fumigatus in an immunocompromised patient. J Infect Dis 1985; 151:196.</a></li><li><a class="nounderline abstract_t">Phillips P, Bryce G, Shepherd J, Mintz D. Invasive external otitis caused by Aspergillus. Rev Infect Dis 1990; 12:277.</a></li><li><a class="nounderline abstract_t">Lyos AT, Malpica A, Estrada R, et al. Invasive aspergillosis of the temporal bone: an unusual manifestation of acquired immunodeficiency syndrome. Am J Otolaryngol 1993; 14:444.</a></li><li><a class="nounderline abstract_t">Gordon G, Giddings NA. Invasive otitis externa due to Aspergillus species: case report and review. Clin Infect Dis 1994; 19:866.</a></li><li><a class="nounderline abstract_t">Harley WB, Dummer JS, Anderson TL, Goodman S. Malignant external otitis due to Aspergillus flavus with fulminant dissemination to the lungs. Clin Infect Dis 1995; 20:1052.</a></li><li><a class="nounderline abstract_t">Bayardelle P, Jolivet-Granger M, Larochelle D. Staphylococcal malignant external otitis. Can Med Assoc J 1982; 126:155.</a></li><li><a class="nounderline abstract_t">Cóser PL, Stamm AE, Lobo RC, Pinto JA. Malignant external otitis in infants. Laryngoscope 1980; 90:312.</a></li><li><a class="nounderline abstract_t">Garcia Rodriguez JA, Montes Martinez I, Gómez González JL, et al. A case of malignant external otitis involving Klebsiella oxytoca. Eur J Clin Microbiol Infect Dis 1992; 11:75.</a></li><li><a class="nounderline abstract_t">Dettelbach MA, Hirsch BE, Weissman JL. Pseudomonas cepacia of the temporal bone: malignant external otitis in a patient with cystic fibrosis. Otolaryngol Head Neck Surg 1994; 111:528.</a></li><li><a class="nounderline abstract_t">Lancaster J, Alderson DJ, McCormick M. Non-pseudomonal malignant otitis externa and jugular foramen syndrome secondary to cyclosporin-induced hypertrichosis in a diabetic renal transplant patient. J Laryngol Otol 2000; 114:366.</a></li><li><a class="nounderline abstract_t">Koleri J, Al Bishawi A, Al-Sheikh I, et al. Beware of covert enemies: Candida orthopsilosis malignant otitis externa with base of the skull osteomyelitis, a case report and review of literature. IDCases 2021; 25:e01163.</a></li><li><a class="nounderline abstract_t">Yao M, Messner AH. Fungal malignant otitis externa due to Scedosporium apiospermum. Ann Otol Rhinol Laryngol 2001; 110:377.</a></li><li><a class="nounderline abstract_t">Chai FC, Auret K, Christiansen K, et al. Malignant otitis externa caused by Malassezia sympodialis. Head Neck 2000; 22:87.</a></li><li><a class="nounderline abstract_t">Favero MS, Carson LA, Bond WW, Petersen NJ. Pseudomonas aeruginosa: growth in distilled water from hospitals. Science 1971; 173:836.</a></li><li><a class="nounderline abstract_t">Yoshpe-Purer Y, Golderman S. Occurrence of Staphylococcus aureus and Pseudomonas aeruginosa in Israeli coastal water. Appl Environ Microbiol 1987; 53:1138.</a></li><li><a class="nounderline abstract_t">Wright DN, Alexander JM. Effect of water on the bacterial flora of swimmers' ears. Arch Otolaryngol 1974; 99:15.</a></li><li><a class="nounderline abstract_t">Salit IE, Miller B, Wigmore M, Smith JA. Bacterial flora of the external canal in diabetics and non-diabetics. Laryngoscope 1982; 92:672.</a></li><li><a class="nounderline abstract_t">Manni JJ, Kuylen K. Clinical and bacteriological studies in otitis externa in Dar es Salaam, Tanzania. Clin Otolaryngol Allied Sci 1984; 9:351.</a></li><li><a class="nounderline abstract_t">Seyfried PL, Cook RJ. Otitis externa infections related to Pseudomonas aeruginosa levels in five Ontario lakes. Can J Public Health 1984; 75:83.</a></li><li><a class="nounderline abstract_t">Rubin J, Yu VL, Kamerer DB, Wagener M. Aural irrigation with water: a potential pathogenic mechanism for inducing malignant external otitis? Ann Otol Rhinol Laryngol 1990; 99:117.</a></li><li><a class="nounderline abstract_t">Dinapoli RP, Thomas JE. Neurologic aspects of malignant external otitis: report of three cases. Mayo Clin Proc 1971; 46:339.</a></li><li><a class="nounderline abstract_t">Schwarz GA, Blumenkrantz MJ, Sundmäker WL. Neurologic complications of malignant external otitis. Neurology 1971; 21:1077.</a></li><li><a class="nounderline abstract_t">John AC, Hopkin NB. An unusual case of necrotizing otitis externa. J Laryngol Otol 1978; 92:259.</a></li><li><a class="nounderline abstract_t">Ford GR, Courteney-Harris RG. Another hazard of ear syringing: malignant external otitis. J Laryngol Otol 1990; 104:709.</a></li><li><a class="nounderline abstract_t">Zikk D, Rapoport Y, Himelfarb MZ. Invasive external otitis after removal of impacted cerumen by irrigation. N Engl J Med 1991; 325:969.</a></li><li><a class="nounderline abstract_t">Davis JC, Gates GA, Lerner C, et al. Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg 1992; 118:89.</a></li><li><a class="nounderline abstract_t">Sreepada GS, Kwartler JA. Skull base osteomyelitis secondary to malignant otitis externa. Curr Opin Otolaryngol Head Neck Surg 2003; 11:316.</a></li><li><a class="nounderline abstract_t">Mani N, Sudhoff H, Rajagopal S, et al. Cranial nerve involvement in malignant external otitis: implications for clinical outcome. Laryngoscope 2007; 117:907.</a></li><li><a class="nounderline abstract_t">Horn KL, Gherini S. Malignant external otitis of childhood. Am J Otol 1981; 2:402.</a></li><li><a class="nounderline abstract_t">Holder CD, Gurucharri M, Bartels LJ, Colman MF. Malignant external otitis with optic neuritis. Laryngoscope 1986; 96:1021.</a></li><li><a class="nounderline abstract_t">Al Maghraoui O, Ezzahraoui R, Hanine MA, et al. Pseudoaneurysm of the intra-petrous internal carotid artery secondary to external malignant otitis. J Med Vasc 2021; 46:148.</a></li><li><a class="nounderline abstract_t">Joshua BZ, Sulkes J, Raveh E, et al. Predicting outcome of malignant external otitis. Otol Neurotol 2008; 29:339.</a></li><li><a class="nounderline abstract_t">Stevens SM, Lambert PR, Baker AB, Meyer TA. Malignant Otitis Externa: A Novel Stratification Protocol for Predicting Treatment Outcomes. Otol Neurotol 2015; 36:1492.</a></li><li><a class="nounderline abstract_t">Rubin J, Curtin HD, Yu VL, Kamerer DB. Malignant external otitis: utility of CT in diagnosis and follow-up. Radiology 1990; 174:391.</a></li><li><a class="nounderline abstract_t">Peleg U, Perez R, Raveh D, et al. Stratification for malignant external otitis. Otolaryngol Head Neck Surg 2007; 137:301.</a></li><li><a class="nounderline abstract_t">Sudhoff H, Rajagopal S, Mani N, et al. Usefulness of CT scans in malignant external otitis: effective tool for the diagnosis, but of limited value in predicting outcome. Eur Arch Otorhinolaryngol 2008; 265:53.</a></li><li><a class="nounderline abstract_t">Al-Noury K, Lotfy A. Computed tomography and magnetic resonance imaging findings before and after treatment of patients with malignant external otitis. Eur Arch Otorhinolaryngol 2011; 268:1727.</a></li><li><a class="nounderline abstract_t">Grandis JR, Curtin HD, Yu VL. Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up. Radiology 1995; 196:499.</a></li><li><a class="nounderline abstract_t">Ismail H, Hellier WP, Batty V. Use of magnetic resonance imaging as the primary imaging modality in the diagnosis and follow-up of malignant external otitis. J Laryngol Otol 2004; 118:576.</a></li><li><a class="nounderline abstract_t">Lee JE, Song JJ, Oh SH, et al. Prognostic value of extension patterns on follow-up magnetic resonance imaging in patients with necrotizing otitis externa. Arch Otolaryngol Head Neck Surg 2011; 137:688.</a></li><li><a class="nounderline abstract_t">Goh JPN, Karandikar A, Loke SC, Tan TY. Skull base osteomyelitis secondary to malignant otitis externa mimicking advanced nasopharyngeal cancer: MR imaging features at initial presentation. Am J Otolaryngol 2017; 38:466.</a></li><li><a class="nounderline abstract_t">Kamalden TMIT, Misron K. A 10-year review of malignant otitis externa: a new insight. Eur Arch Otorhinolaryngol 2022; 279:2837.</a></li><li><a class="nounderline abstract_t">Ostfeld E, Aviel A, Pelet D. Malignant external otitis: The diagnostic value of bone scintigraphy. Laryngoscope 1981; 91:960.</a></li><li><a class="nounderline abstract_t">Garty I, Rosen G, Holdstein Y. The radionuclide diagnosis, evaluation and follow-up of malignant external otitis (MEO). The value of immediate blood pool scanning. J Laryngol Otol 1985; 99:109.</a></li><li><a class="nounderline abstract_t">Gherini SG, Brackmann DE, Bradley WG. Magnetic resonance imaging and computerized tomography in malignant external otitis. Laryngoscope 1986; 96:542.</a></li><li><a class="nounderline abstract_t">Hardoff R, Gips S, Uri N, et al. Semiquantitative skull planar and SPECT bone scintigraphy in diabetic patients: differentiation of necrotizing (malignant) external otitis from severe external otitis. J Nucl Med 1994; 35:411.</a></li><li><a class="nounderline abstract_t">Stokkel MP, Boot CN, van Eck-Smit BL. SPECT gallium scintigraphy in malignant external otitis: initial staging and follow-up. Case reports. Laryngoscope 1996; 106:338.</a></li><li><a class="nounderline abstract_t">Paramsothy M, Khanijow V, Ong TO. Use of gallium-67 in the assessment of response to antibiotic therapy in malignant otitis externa--a case report. Singapore Med J 1997; 38:347.</a></li><li><a class="nounderline abstract_t">Amorosa L, Modugno GC, Pirodda A. Malignant external otitis: review and personal experience. Acta Otolaryngol Suppl 1996; 521:3.</a></li><li><a class="nounderline abstract_t">Levin WJ, Shary JH 3rd, Nichols LT, Lucente FE. Bone scanning in severe external otitis. Laryngoscope 1986; 96:1193.</a></li><li><a class="nounderline abstract_t">Uri N, Gips S, Front A, et al. Quantitative bone and 67Ga scintigraphy in the differentiation of necrotizing external otitis from severe external otitis. Arch Otolaryngol Head Neck Surg 1991; 117:623.</a></li><li><a class="nounderline abstract_t">Stokkel MP, Takes RP, van Eck-Smit BL, Baatenburg de Jong RJ. The value of quantitative gallium-67 single-photon emission tomography in the clinical management of malignant external otitis. Eur J Nucl Med 1997; 24:1429.</a></li><li><a class="nounderline abstract_t">Galletti F, Cammaroto G, Galletti B, et al. Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role? Eur Arch Otorhinolaryngol 2015; 272:1377.</a></li><li><a class="nounderline abstract_t">Mattucci KF, Setzen M, Galantich P. Necrotizing otitis externa occurring concurrently with epidermoid carcinoma. Laryngoscope 1986; 96:264.</a></li><li><a class="nounderline abstract_t">Grandis JR, Hirsch BE, Yu VL. Simultaneous presentation of malignant external otitis and temporal bone cancer. Arch Otolaryngol Head Neck Surg 1993; 119:687.</a></li><li><a class="nounderline abstract_t">Berenholz L, Katzenell U, Harell M. Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. Laryngoscope 2002; 112:1619.</a></li><li><a class="nounderline abstract_t">Carlton DA, Perez EE, Smouha EE. Malignant external otitis: The shifting treatment paradigm. Am J Otolaryngol 2018; 39:41.</a></li><li><a class="nounderline abstract_t">Franco-Vidal V, Blanchet H, Bebear C, et al. Necrotizing external otitis: a report of 46 cases. Otol Neurotol 2007; 28:771.</a></li><li><a class="nounderline abstract_t">Walton J, Coulson C. Fungal malignant otitis externa with facial nerve palsy: tissue biopsy AIDS diagnosis. Case Rep Otolaryngol 2014; 2014:192318.</a></li><li><a class="nounderline abstract_t">Mion M, Bovo R, Marchese-Ragona R, Martini A. Outcome predictors of treatment effectiveness for fungal malignant external otitis: a systematic review. Acta Otorhinolaryngol Ital 2015; 35:307.</a></li><li><a class="nounderline abstract_t">Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.</a></li><li><a class="nounderline abstract_t">Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387:760.</a></li><li><a class="nounderline abstract_t">Finer G, Greenberg D, Leibovitz E, et al. Conservative treatment of malignant (invasive) external otitis caused by Aspergillus flavus with oral itraconazole solution in a neutropenic patient. Scand J Infect Dis 2002; 34:227.</a></li><li><a class="nounderline abstract_t">Soliman AE. A rare case of malignant otitis externa in a non-diabetic patient. J Laryngol Otol 1978; 92:811.</a></li><li><a class="nounderline abstract_t">Joachims HZ, Danino J, Raz R. Malignant external otitis: treatment with fluoroquinolones. Am J Otolaryngol 1988; 9:102.</a></li><li><a class="nounderline abstract_t">Leggett JM, Prendergast K. Malignant external otitis: the use of oral ciprofloxacin. J Laryngol Otol 1988; 102:53.</a></li><li><a class="nounderline abstract_t">Morrison GA, Bailey CM. Relapsing malignant otitis externa successfully treated with ciprofloxacin. J Laryngol Otol 1988; 102:872.</a></li><li><a class="nounderline abstract_t">Sadé J, Lang R, Goshen S, Kitzes-Cohen R. Ciprofloxacin treatment of malignant external otitis. Am J Med 1989; 87:138S.</a></li><li><a class="nounderline abstract_t">Hickey SA, Ford GR, O'Connor AF, et al. Treating malignant otitis with oral ciprofloxacin. BMJ 1989; 299:550.</a></li><li><a class="nounderline abstract_t">Rubin J, Stoehr G, Yu VL, et al. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg 1989; 115:1063.</a></li><li><a class="nounderline abstract_t">Levenson MJ, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). Laryngoscope 1991; 101:821.</a></li><li><a class="nounderline abstract_t">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li class="breakAll">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.903.</li><li><a class="nounderline abstract_t">Orenstein DM, Pattishall EN, Noyes BE, et al. Safety of ciprofloxacin in children with cystic fibrosis. Clin Pediatr (Phila) 1993; 32:504.</a></li><li><a class="nounderline abstract_t">Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33:194.</a></li><li><a class="nounderline abstract_t">Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005; 41:470.</a></li><li><a class="nounderline abstract_t">Shupak A, Greenberg E, Hardoff R, et al. Hyperbaric oxygenation for necrotizing (malignant) otitis externa. Arch Otolaryngol Head Neck Surg 1989; 115:1470.</a></li><li><a class="nounderline abstract_t">Mader JT, Love JT. Malignant external otitis. Cure with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol 1982; 108:38.</a></li><li><a class="nounderline abstract_t">Lucente FE, Parisier SC, Som PM, Arnold LM. Malignant external otitis: a dangerous misnomer? Otolaryngol Head Neck Surg 1982; 90:266.</a></li><li><a class="nounderline abstract_t">Lucente FE, Parisier SC, Som PM. Complications of the treatment of malignant external otitis. Laryngoscope 1983; 93:279.</a></li><li><a class="nounderline abstract_t">Phillips JS, Jones SE. Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa. Cochrane Database Syst Rev 2013; :CD004617.</a></li></ol></div><div id="topicVersionRevision">Topic 3413 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14720566" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16995959" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046354" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4970362" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728285" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Necrotizing 'malignant' external otitis caused by Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1449188" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Blastomycotic cranial osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6197469" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1863417" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Invasive external otitis caused by Aspergillus fumigatus in two patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2288401" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : [Malignant otitis externa and HIV antibodies. A case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1775861" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fatal necrotizing otitis externa in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554824" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Life-threatening Pseudomonas aeruginosa infections in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7805599" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Malignant otitis externa in AIDS patients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111373" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Necrotizing external otitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580133" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Necrotizing external otitis caused by Aspergillus fumigatus: computed tomography and high resolution magnetic resonance imaging in an AIDS patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20869559" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Errors in the diagnosis and management of necrotizing otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3281697" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Necrotizing otitis externa due to Aspergillus in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Invasive external otitis caused by Aspergillus fumigatus in an immunocompromised patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184497" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Invasive external otitis caused by Aspergillus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285317" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Invasive aspergillosis of the temporal bone: an unusual manifestation of acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7893871" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Invasive otitis externa due to Aspergillus species: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795050" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Malignant external otitis due to Aspergillus flavus with fulminant dissemination to the lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7059891" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Staphylococcal malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6986525" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Malignant external otitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1563390" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A case of malignant external otitis involving Klebsiella oxytoca.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524007" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pseudomonas cepacia of the temporal bone: malignant external otitis in a patient with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10912267" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Non-pseudomonal malignant otitis externa and jugular foramen syndrome secondary to cyclosporin-induced hypertrichosis in a diabetic renal transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34094863" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Beware of covert enemies: Candida orthopsilosis malignant otitis externa with base of the skull osteomyelitis, a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11307916" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fungal malignant otitis externa due to Scedosporium apiospermum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585610" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malignant otitis externa caused by Malassezia sympodialis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4999114" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pseudomonas aeruginosa: growth in distilled water from hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3111367" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Occurrence of Staphylococcus aureus and Pseudomonas aeruginosa in Israeli coastal water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4203177" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of water on the bacterial flora of swimmers' ears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087628" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bacterial flora of the external canal in diabetics and non-diabetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6532606" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical and bacteriological studies in otitis externa in Dar es Salaam, Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6423256" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Otitis externa infections related to Pseudomonas aeruginosa levels in five Ontario lakes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301865" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Aural irrigation with water: a potential pathogenic mechanism for inducing malignant external otitis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4996123" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neurologic aspects of malignant external otitis: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5001162" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurologic complications of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632666" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : An unusual case of necrotizing otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230579" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Another hazard of ear syringing: malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1881425" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Invasive external otitis after removal of impacted cerumen by irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728284" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant hyperbaric oxygen in malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14502060" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Skull base osteomyelitis secondary to malignant otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473694" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cranial nerve involvement in malignant external otitis: implications for clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6789684" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Malignant external otitis of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747688" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Malignant external otitis with optic neuritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33990290" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pseudoaneurysm of the intra-petrous internal carotid artery secondary to external malignant otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317396" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Predicting outcome of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375971" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Malignant Otitis Externa: A Novel Stratification Protocol for Predicting Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2104989" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Malignant external otitis: utility of CT in diagnosis and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666260" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Stratification for malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17680261" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Usefulness of CT scans in malignant external otitis: effective tool for the diagnosis, but of limited value in predicting outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21400256" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Computed tomography and magnetic resonance imaging findings before and after treatment of patients with malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7617867" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15318971" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of magnetic resonance imaging as the primary imaging modality in the diagnosis and follow-up of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768413" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prognostic value of extension patterns on follow-up magnetic resonance imaging in patients with necrotizing otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483146" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Skull base osteomyelitis secondary to malignant otitis externa mimicking advanced nasopharyngeal cancer: MR imaging features at initial presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226993" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A 10-year review of malignant otitis externa: a new insight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6454033" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Malignant external otitis: The diagnostic value of bone scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3156198" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The radionuclide diagnosis, evaluation and follow-up of malignant external otitis (MEO). The value of immediate blood pool scanning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3458018" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Magnetic resonance imaging and computerized tomography in malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113885" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Semiquantitative skull planar and SPECT bone scintigraphy in diabetic patients: differentiation of necrotizing (malignant) external otitis from severe external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8614200" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : SPECT gallium scintigraphy in malignant external otitis: initial staging and follow-up. Case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9364890" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of gallium-67 in the assessment of response to antibiotic therapy in malignant otitis externa--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8929671" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Malignant external otitis: review and personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3773615" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bone scanning in severe external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2036183" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Quantitative bone and 67Ga scintigraphy in the differentiation of necrotizing external otitis from severe external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371879" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The value of quantitative gallium-67 single-photon emission tomography in the clinical management of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24534898" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Technetium-99m (⁹⁹mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3951301" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Necrotizing otitis externa occurring concurrently with epidermoid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8499104" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Simultaneous presentation of malignant external otitis and temporal bone cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352675" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042067" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Malignant external otitis: The shifting treatment paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721365" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Necrotizing external otitis: a report of 46 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24649388" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fungal malignant otitis externa with facial nerve palsy: tissue biopsy AIDS diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26824911" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcome predictors of treatment effectiveness for fungal malignant external otitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167683" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684607" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12030404" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Conservative treatment of malignant (invasive) external otitis caused by Aspergillus flavus with oral itraconazole solution in a neutropenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/701982" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A rare case of malignant otitis externa in a non-diabetic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177762" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Malignant external otitis: treatment with fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343563" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Malignant external otitis: the use of oral ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3199005" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Relapsing malignant otitis externa successfully treated with ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2589357" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Ciprofloxacin treatment of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507066" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treating malignant otitis with oral ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2504254" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1865729" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8403750" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Safety of ciprofloxacin in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835137" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16028153" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2818901" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hyperbaric oxygenation for necrotizing (malignant) otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6459078" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Malignant external otitis. Cure with adjunctive hyperbaric oxygen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6810275" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Malignant external otitis: a dangerous misnomer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6834949" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Complications of the treatment of malignant external otitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728650" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
